
We see precision medicine as the future of cancer care.
Let’s make it happen, together. Our cutting-edge genomic profiling technology covers all cancer and sample types to accelerate precision cancer care. We work closely with you to solve your specific needs, with a relentless focus on quality and efficiency.
EXPERIENCE MATTERS.WE HAVE IT.
Services for Oncology Clinical Trials
-
- NGS services
- CDx + LDT strategy
- Project management
- Sample logistics and storage
- Data analysis and storage
- Customized QC/QA solutions
NGS Services for Precision Oncology
-
- Pan-cancer genetic test for solid tumors
- ctDNA liquid biopsy
- Over 30 clinical NGS testing products for different cancers
- Over 10 products under development
NGS-based CDx Kit for Diagnosis
-
- Essencare ™ EGFR/ALK/ROS1/BRAF/KRAS/HER2 mutant testing kit (reversible terminator technology)
NGS Services for Research
-
- DNA sequencing
- WGS, WES
- Targeted panel sequencing
- DNA methylation sequencing
- Customer-made library sequencing
- RNA sequencing
- Whole transcriptome sequencing
- Small RNA sequencing, including miRNA, siRNA and piRNA
- Circular RNA sequencing
- DNA sequencing

600,000+
SAMPLES
sequenced for cancer patients

600+
HOSPITALS
in which our products are used

30+
PRODUCTS
for solid tumors & blood cancers

2000+
CLINICAL PROJECTS
in translational research

400+
PUBLICATIONS
in the past 5 years
Certified to the highest international clinical lab standards




Genomic Testing
The most diverse range of cancer genomic testing available
Using comprehensive genomic insights, we help match cancer patients to optimal treatments, including targeted therapy and immunotherapy. Our pan-cancer panel analyzes 400+ genes, while specific panels target individual cancer types. We partner with you to give you the insights you need to take action – from treatment decisions to new therapy development.
Research Services
A strong partner to drive research forward
Our company is built on a strong foundation of research, with deep scientific expertise and active R&D. We have 2000+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. We offer full research services, including project design & management, next-generation sequencing, QC/QA and data analysis, tailored to your needs.


OUR TECHNOLOGY
Reliable and fast is possible
We are continuously evolving our sequencing technology as we gain new knowledge. This ensures an optimized workflow – from sample preparation, mutation calling and data mining to machine-learning and exclusive genomic databases – and a very high sequencing capacity. To date, we have sequenced 600,000+ samples (280,000+ liquid biopsy samples), with high sensitivity and specificity and a turnaround time of just five business days.
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.
Our News
June 13, 2022
Geneseeq Multicancer Early Detection Study Yields Promising Results
TORONTO, June 13, 2022 - Early cancer detection can significantly…
May 31, 2022
Geneseeq at ASCO 2022
The American Society of Clinical Oncology (ASCO) Annual Meeting is…
May 19, 2022
Geneseeq collaborates on another minimal residual disease study in chemoradiotherapy-treated inoperable localized non-small cell lung cancer patients.
TORONTO, May 19th, 2022 - Nearly one-third of non-small cell lung…
April 5, 2022
Geneseeq Presents 9 Posters at AACR 2022
TORONTO, April 5—Geneseeq and collaborators are excited to present…
January 4, 2022
Geneseeq’s cancer early detection study series DECIPHER yield another publication in HEPATOLOGY to explore the performance of cfDNA fragmentomics in liver cancer
TORONTO, January 04, 2022 - Early detection of primary liver cancer…
November 11, 2021
Geneseeq Forms Lung Cancer Strategic Partnerships with Takeda and AstraZeneca on the Same Day
TORONTO – NOV 11, 2021 - On November 7th, during the 4th China…
November 8, 2021
Geneseeq collaborates on research identifying predictive biomarkers for guiding personalized adjuvant treatment in resected EGFR-positive non-small cell lung cancer
TORONTO, November 8, 2021 - Adjuvant treatment with gefitinib, a good…
October 13, 2021
Geneseeq and Zai Lab Announce Strategic Collaboration to Advance Cancer Drug R&D
TORONTO, Oct. 13, 2021 - Geneseeq Technology Inc. ("Geneseeq") and…
September 15, 2021
Geneseeq Presents 10 studies on MRD, early cancer detection, cancer diagnosis and cancer biology research at EMSO 2021
The European Society of Medical Oncology Annual Conference (ESMO…
August 31, 2021
Geneseeq Study Evaluates ctDNA MRD to Predict Response to Therapy and Assess Prognosis in Locally Advanced Rectal Cancer
TORONTO, August 31 - Currently, there is no reliable clinical…